Advancements in microfluidic technologies for isolation and early detection of circulating cancer-related biomarkers.
Analyst
; 143(13): 2971-2991, 2018 Jun 25.
Article
em En
| MEDLINE
| ID: mdl-29790491
ABSTRACT
Early stage detection of cancer is essential for the improved long-term survival of patients. Currently, costly, extensively complex and invasive procedures, such as surgical tissue biopsies, are used for cancer screening. Thus, over the past few decades, advancements in microfluidics and lab-on-a-chip approaches have been made to develop minimally invasive and miniaturized platforms to identify and segregate circulating cancer biomarkers such as exosomes, circulating tumor cells (CTCs) and cell-free DNA (cfDNA) from body fluids. Our study presents a comprehensive overview of all such microfluidics based approaches for point-of-care cancer diagnostics, which have proven to require significantly reduced sample volumes with cost effective and minimally invasive criteria. We have also discussed the need for integrated and more efficient devices to further advance these technologies to be suitable for liquid biopsy in the clinical settings.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Biomarcadores Tumorais
/
Dispositivos Lab-On-A-Chip
/
Células Neoplásicas Circulantes
Tipo de estudo:
Diagnostic_studies
/
Prognostic_studies
/
Screening_studies
Limite:
Humans
Idioma:
En
Revista:
Analyst
Ano de publicação:
2018
Tipo de documento:
Article
País de afiliação:
Estados Unidos